Clinical trials: sponsored by The Netherlands Cancer Institute
Urologic Neoplasms, Urogenital Neoplasms
Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer
This is a single-armed, single-centre, non-blinded phase II trial to assess efficacy of induction chemo-immunotherapy for resectable node-positive squamous cell carcinoma of the penis
- Conditions
- Urologic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases, Penile Cancer
- Trial name
- PRIAM (NCT06353906)
- Testing
- Carboplatin/Paclitaxel, Pembrolizumab, Partial or total penectomy with inguinal and/or pelvic lymph node dissection
- Where
- 2 sites in Belgium, Netherlands
- Volunteers
- 27 people
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer
Chemosensitivity During Phases of the Menstrual Cycle in Breast Cancer Patients
This study is a prospective, multicenter study in which a serum sample will be collected at the day of starting neo adjuvant treatment in breast cancer patients
- Trial name
- Chemosense (NCT06273800)
- Testing
- Blood sample
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- The Netherlands Cancer Institute
HER2-positive Breast Cancer
Basket Study for Oligo-metastatic Breast Cancer
The study will include patients with HER2-positive breast cancer and 1- 3 distant metastatic lesions, all amenable for curative intervention. Patients will be stratified by prior therapy and ER expression.
- Trial name
- ANISE (NCT05982678)
- Testing
- Trastuzumab deruxtecan
- Where
- Netherlands
- Volunteers
- 72 people
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer
Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer
Triple negative breast cancer (TNBC) is a difficult to treat molecular subtype with a poor survival. TNBC can be divided into at least two molecular entities; BRCA-like and non-BRCA-like.
- Trial name
- Triple-B (NCT01898117)
- Testing
- Carbo/cyclo, Carbo/cyclo + atezolizumab, Paclitaxel
- Where
- 49 sites in Netherlands
- Volunteers
- 304 people
- Sponsor
- The Netherlands Cancer Institute
Renal Cell Carcinoma
Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer
The NESCIO-trial is a multicenter, randomized, open-label, three-arm phase II trial investigating different combinations of neoadjuvant immunotherapy in patients with primary, resectable, intermediate to high-risk, clear-cell…
- Trial name
- NESCIO (NCT05148546)
- Testing
- Neoadjuvant nivolumab, Neoadjuvant ipilimumab, Neoadjuvant relatlimab
- Where
- 2 sites in Netherlands, United Kingdom
- Volunteers
- 69 people
- Sponsor
- The Netherlands Cancer Institute
Colorectal Cancer Metastatic
LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)
Part I of this study is designed to identify the recommended phase 2 dose (RP2D) of the combination regimen of LY3200882/capecitabine as second line treatment in patients with 5-FU or capecitabine resistant CRC.
- Trial name
- NCT04031872
- Testing
- LY3200882
- Sponsor
- The Netherlands Cancer Institute
Liver Metastases
Functional Liver After SBRT
In this study, the investigators aim to determine the dose-effect relationship between radiation dose and liver function by performing a hepatobiliary scintigraphy (HEBIS) before and after stereotactic body radiotherapy (SBRT)…
- Trial name
- FAFOR (NCT07033364)
- Testing
- Functional liver imaging using hepatobiliary scintigraphy (HEBIS)
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- The Netherlands Cancer Institute
Cutaneous Squamous Cell Carcinoma
Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery
To determine the histopathological response rate to neo-adjuvant nivolumab and nivolumab plus ipilimumab at time of standard of care(surgery ± radiotherapy).in patients with cutaneous squamous cell carcinoma.
- Trial name
- MATISSE (NCT04620200)
- Testing
- Nivolumab, Ipilimumab
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- The Netherlands Cancer Institute
Early-onset Colorectal Cancer
Earlier Detection and Optimization of Treatment and Prognosis for Patients With Early-onset Colorectal Cancer
The study aims to collect high quality clinical data on lifestyle and patient biomaterials prior to start or during / after treatment of early-onset colorectal cancer (EOCRC) and to inform on treatment and survival outcomes of…
- Trial name
- BIO-EOCRC (NCT06568679)
- Testing
- No intervention; observational
- Where
- Netherlands
- Volunteers
- 300 people
- Sponsor
- The Netherlands Cancer Institute
Colon Cancer
Vinorelbine in Advanced BRAF-like Colon Cancer
Vecchione et al showed that suppression of RANBP2 results in mitotic defects only in BRAF-like colon cancer (CC) cells, which leads to cell death.
- Trial name
- EORTC1616 (NCT03482362)
- Testing
- Vinorelbine Tartrate
- Where
- Netherlands
- Volunteers
- 1 people
- Sponsor
- The Netherlands Cancer Institute
Drug Safety Biomarkers
Food-effect Study on Uracil and Dihydrouracil Levels as a Diagnostic Marker of Dihydropyrimidine Dehydrogenase Activity
Healthy volunteer food-effect study to determine the effect of food on uracil and dihydrouracil levels in plasma
- Trial name
- NCT02718664
- Testing
- Test meal (breakfast)
- Where
- Netherlands
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- The Netherlands Cancer Institute
Prostate Cancer, Cervical Cancer
Feasibility of CBCT-Guided Online Adaptive Radiotherapy (FASCINATE)
The accuracy of radiotherapy can be increased by correcting for geometric uncertainties and changes between radiotherapy fractions.
- Conditions
- Prostate Cancer, Cervical Cancer, Bladder Cancer, Lung Cancer
- Trial name
- FASCINATE (NCT06691776)
- Testing
- online CBCT-guided adaptive radiation therapy using a new software
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- The Netherlands Cancer Institute
FIGO Stage III Ovarian Cancer, Peritoneal Cancer
Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian Cancer
Cytoreductive surgery (CRS) with the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) is used in current clinical practice in selected patients with advanced ovarian cancer.
- Conditions
- FIGO Stage III Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Carcinoma
- Trial name
- CisCon (NCT05406674)
- Testing
- Cisplatin 100 mg/m2, Cisplatin 40 mg/l
- Where
- 2 sites in Netherlands
- Volunteers
- 40 people
- Sponsor
- The Netherlands Cancer Institute
Stomach Neoplasm, Peritoneal Carcinomatosis
Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination.
A randomized controlled two-armed phase III trial for gastric cancer patients with peritoneal dissemination. Randomization between gastrectomy + cytoreductive surgery + HIPEC (experimental arm) and palliative systemic…
- Trial name
- PERISCOPEII (NCT03348150)
- Testing
- Cytoreductive surgery + Gastrecomy, Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
- Where
- Netherlands
- Volunteers
- 102 people
- Sponsor
- The Netherlands Cancer Institute
Malignant Solid Tumour
Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors
The purpose of this prospective study is to determine the safety and feasibility of pharmacokinetically (PK) guided dosing of sunitinib in 30 patients.
- Trial name
- NCT01286896
- Testing
- Sunitinib
- Where
- Netherlands
- Volunteers
- 43 people
- Sponsor
- The Netherlands Cancer Institute
Melanoma, Skin Neoplasms
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma
This is a mono-center open-label proof-of-concept pharmacologic study to explore the efficacy and safety of vorinostat in advanced BRAF mutated melanoma, which became resistant for BRAF-inhibitors or the combination of BRAF- and…
- Trial name
- NCT02836548
- Testing
- Vorinostat
- Where
- Netherlands
- Volunteers
- 33 people
- Sponsor
- The Netherlands Cancer Institute
Colorectal Cancer
Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC
This is a phase I/II multi-center open-label proof of concept study, consisting of two parts. Part A of this study is designed to identify the recommended phase 2 dose (RP2D) of the combination regimen of dacomitinib plus…
- Trial name
- M13DAP (NCT02039336)
- Testing
- Dacomitinib, PD-0325901, Docetaxel
- Where
- 3 sites in Netherlands
- Volunteers
- 35 people
- Sponsor
- The Netherlands Cancer Institute
mCRPC, Male Urogenital Diseases
The Radium-select Study
Radium-223 is an established radionuclide therapy for patients with metastatic castration resistant prostate cancer (mCRPC) and symptomatic bone metastasis.
- Trial name
- NCT06659926
- Testing
- 68Ga-PSMA-PET/CT scan
- Where
- 5 sites in Netherlands
- Volunteers
- 60 people
- Sponsor
- The Netherlands Cancer Institute
Colorectal Cancer
Lapatinib Plus Trametinib in KRAS Mutant NSCLC
This is an open-label phase I/II multi-center study consisting of two parts. Part A of this study is designed to identify the recommended phase 2 dose (RP2D) of lapatinib combined with trametinib in patients with metastatic KRASm…
- Trial name
- M14LTK (NCT02230553)
- Testing
- Lapatinib, trametinib
- Where
- Netherlands
- Volunteers
- 35 people
- Sponsor
- The Netherlands Cancer Institute
Non Hodgkin Lymphoma, DLBCL
Cardiotoxicity and Other Late Effects After Radiotherapy and Immuno-chemoTherapy in Non-Hodgkin lYmphoma
Survivors of non-Hodgkin lymphoma and a control group will be screened for (sub)clinical cardiovascular disease, to assess the influence of contemporary treatments on risk and burden of (sub)clinical cardiovascular disease and…
- Conditions
- Non Hodgkin Lymphoma, DLBCL, Cardiovascular Diseases, Cardiomyopathies
- Trial name
- CLARITY (NCT07041827)
- Testing
- Cardiovascular assessment
- Where
- Netherlands
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- The Netherlands Cancer Institute